Tier 4 — mechanistic

Nicotinamide riboside and pterostilbene reduces frequency and severity of undesirable symptoms of the menopause transition: an open-label, pilot clinical trial

Holmes HE, Srivastava K, Scalici JM, Dhuguru J, Shea AE, Migaud ME, Dellinger RW
Frontiers in aging 2026 7; 1773667

Bibliography

PubMed
PMID 42211736
PubMed Central
PMC13213337
DOI
10.3389/fragi.2026.1773667
Funding
Elysium Health funded the study.
Competing interests
Several authors were Elysium Health employees; another author was employed by Aragen Life Sciences.

Study snapshot

DesignOpen-label human intervention study
ModelHuman participants
Sample40 women; 32 with self-reported menopause-transition symptoms
InterventionNR 250 mg plus pterostilbene 50 mg/day
Duration7 days
EndpointsMenopause-transition symptoms; urinary estrogens

What the study showed, in plain terms

Women reporting menopause-transition symptoms described less bloating, hot flashes and poor sleep after one week of the combination.

Key findings

Women reporting menopause-transition symptoms described less bloating, hot flashes and poor sleep after one week of the combination.

What this study can and cannot tell us

Open-label, uncontrolled, very short study with self-reported outcomes. It cannot establish NR-specific efficacy or replacement of standard menopause care.

Related papers in the corpus

Tier 2
Nicotinamide riboside and pterostilbene reduces markers of hepatic inflammation in NAFLD: A double-blind, placebo-controlled clinical trial
Dellinger RW et al. · Hepatology (Baltimore, Md.) · 2023
Tier 2
Effect of the Mediterranean diet supplemented with nicotinamide riboside and pterostilbene and/or coconut oil on anthropometric variables in amyotrophic lateral sclerosis. A pilot study
Carrera-Juliá S et al. · Frontiers in nutrition · 2023
Tier 2
A randomized placebo-controlled trial of nicotinamide riboside and pterostilbene supplementation in experimental muscle injury in elderly individuals
Jensen JB et al. · JCI insight · 2022
Tier 2
Nicotinamide riboside with pterostilbene (NRPT) increases NAD + in patients with acute kidney injury (AKI): a randomized, double-blind, placebo-controlled, stepwise safety study of escalating doses of NRPT in patients with AKI
Simic P et al. · BMC nephrology · 2020
Tier 2
Efficacy and tolerability of EH301 for amyotrophic lateral sclerosis: a randomized, double-blind, placebo-controlled human pilot study
de la Rubia JE et al. · Amyotrophic lateral sclerosis & frontotemporal degeneration · 2019
Tier 2
Repeat dose NRPT (nicotinamide riboside and pterostilbene) increases NAD + levels in humans safely and sustainably: a randomized, double-blind, placebo-controlled study
Dellinger RW et al. · NPJ aging and mechanisms of disease · 2017

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology